{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:20:26Z","timestamp":1730870426794,"version":"3.28.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00105-024-05416-6","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:02:03Z","timestamp":1727193723000},"page":"845-851","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Arzneimitteltherapiesicherheit in Schwangerschaft und Stillzeit","Drug therapy safety during pregnancy and breastfeeding"],"prefix":"10.1007","volume":"75","author":[{"given":"Johannes","family":"Wohlrab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adina","family":"Eichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"5416_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00105-016-3921-0","volume":"68","author":"S Grunewald","year":"2017","unstructured":"Grunewald\u00a0S, Staubach\u00a0P (2017) Dermatologische topische und Systemtherapie in der Schwangerschaft. Hautarzt 68:127\u2013135","journal-title":"Hautarzt"},{"key":"5416_CR2","doi-asserted-by":"publisher","first-page":"796590","DOI":"10.1155\/2012\/796590","volume":"2012","author":"D Matsui","year":"2012","unstructured":"Matsui\u00a0D (2012) Adherence with drug therapy in pregnancy. Obstet Gynecol Int 2012:796590","journal-title":"Obstet Gynecol Int"},{"key":"5416_CR3","doi-asserted-by":"crossref","unstructured":"Zaccaria C, Piccolo L, Gordillo-Maranon M et\u00a0al (2024) Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A\u00a0Novel Algorithm Developed in EudraVigilance. Drug Saf","DOI":"10.1007\/s40264-024-01448-y"},{"key":"5416_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00105-010-2006-8","volume":"61","author":"J Wohlrab","year":"2010","unstructured":"Wohlrab\u00a0J (2010) Dermatotherapie in der Schwangerschaft. Hautarzt 61:1046\u20131051","journal-title":"Hautarzt"},{"key":"5416_CR5","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1111\/bcp.14649","volume":"88","author":"D Sun","year":"2022","unstructured":"Sun\u00a0D, Hutson\u00a0JR, Garcia-Bournissen\u00a0F (2022) Drug therapy during pregnancy. Br J Clin Pharmacol 88:4247\u20134249","journal-title":"Br J Clin Pharmacol"},{"key":"5416_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/srt.12465","volume":"24","author":"G Boyer","year":"2018","unstructured":"Boyer\u00a0G, Lachmann\u00a0N, Bellemere\u00a0G et\u00a0al (2018) Effects of pregnancy on skin properties: A\u00a0biomechanical approach. Skin Res Technol 24:551\u2013556","journal-title":"Skin Res Technol"},{"key":"5416_CR7","unstructured":"(2019) Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, Rote-Hand-Brief zu Retinoiden, Aktualisierungen zu Teratogenit\u00e4t und neuropsychiatrischen Erkrankungen. https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2019\/retinoide-rhb.pdf?__blob=publicationFile"},{"key":"5416_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fpubh.2020.00350","volume":"8","author":"T Schink","year":"2020","unstructured":"Schink\u00a0T, Wentzell\u00a0N, Dathe\u00a0K et\u00a0al (2020) Estimating the Beginning of Pregnancy in German Claims Data: Development of an Algorithm With a\u00a0Focus on the Expected Delivery Date. Front Public Health 8:350","journal-title":"Front Public Health"},{"key":"5416_CR9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/cpt.2843","volume":"113","author":"D Kappel","year":"2023","unstructured":"Kappel\u00a0D, Sahin\u00a0L, Yao\u00a0L et\u00a0al (2023) A\u00a0Comparison of FDA and EMA Pregnancy and Lactation Labeling. Clin Pharmacol Ther 113:1251\u20131257","journal-title":"Clin Pharmacol Ther"},{"key":"5416_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/acem.12691","volume":"22","author":"YC Kaplan","year":"2015","unstructured":"Kaplan\u00a0YC, Karadas\u00a0B, Kaya-Temiz\u00a0T (2015) Defining a\u00a0medication class as a\u00a0teratogen: may the evidence be with you and not the FDA Pregnancy Risk Categories. Acad Emerg Med 22:769","journal-title":"Acad Emerg Med"},{"key":"5416_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/BF02849994","volume":"24","author":"A Basgul","year":"2007","unstructured":"Basgul\u00a0A, Akici\u00a0A, Uzuner\u00a0A et\u00a0al (2007) Drug utilization and teratogenicity risk categories during pregnancy. Adv Ther 24:68\u201380","journal-title":"Adv Ther"},{"key":"5416_CR12","first-page":"239","volume":"56","author":"R Law","year":"2010","unstructured":"Law\u00a0R, Bozzo\u00a0P, Koren\u00a0G et\u00a0al (2010) FDA pregnancy risk categories and the CPS: do they help or are they a\u00a0hindrance? Can Fam Physician 56:239\u2013241","journal-title":"Can Fam Physician"},{"key":"5416_CR13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/art.40508","volume":"70","author":"MEB Clowse","year":"2018","unstructured":"Clowse\u00a0MEB, Scheuerle\u00a0AE, Chambers\u00a0C et\u00a0al (2018) Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a\u00a0Pharmacovigilance Safety Database. Arthritis Rheumatol 70:1399\u20131407","journal-title":"Arthritis Rheumatol"},{"key":"5416_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1699-0463.1995.tb01129.x","volume":"103","author":"TS Jensen","year":"1995","unstructured":"Jensen\u00a0TS, Matre\u00a0R (1995) Fc gamma-receptor activity in the developing human placenta. Apmis 103:433\u2013438","journal-title":"Apmis"},{"key":"5416_CR15","first-page":"376","volume":"16","author":"J Wohlrab","year":"2018","unstructured":"Wohlrab\u00a0J, Staubach\u00a0P, Augustin\u00a0M et\u00a0al (2018) S2k-Leitlinie zum Gebrauch von Pr\u00e4parationen zur lokalen Anwendung auf der Haut (Topika). J\u00a0Dtsch Dermatol Ges 16:376\u2013392","journal-title":"J Dtsch Dermatol Ges"},{"key":"5416_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/jps.20233","volume":"94","author":"RH Neubert","year":"2005","unstructured":"Neubert\u00a0RH, Schmalfuss\u00a0U, Wolf\u00a0R et\u00a0al (2005) Microemulsions as colloidal vehicle systems for dermal drug delivery. Part V:\u00a0Microemulsions without and with glycolipid as penetration enhancer. J\u00a0Pharm Sci 94:821\u2013827","journal-title":"J Pharm Sci"},{"key":"5416_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/jphp.12334","volume":"67","author":"A Herman","year":"2015","unstructured":"Herman\u00a0A, Herman\u00a0AP (2015) Essential oils and their constituents as skin penetration enhancer for transdermal drug delivery: a\u00a0review. J\u00a0Pharm Pharmacol 67:473\u2013485","journal-title":"J Pharm Pharmacol"},{"key":"5416_CR18","first-page":"554","volume":"19","author":"J Wohlrab","year":"2021","unstructured":"Wohlrab\u00a0J (2021) Influence of keratolytics on cutaneous pharmacokinetics of glucocorticoids. J\u00a0Dtsch Dermatol Ges 19:554\u2013561","journal-title":"J Dtsch Dermatol Ges"},{"key":"5416_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/pds.5512","volume":"32","author":"EA Suarez","year":"2023","unstructured":"Suarez\u00a0EA, Nguyen\u00a0M, Zhang\u00a0D et\u00a0al (2023) Novel methods for pregnancy drug safety surveillance in the FDA Sentinel System. Pharmacoepidemiol Drug Saf 32:126\u2013136","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5416_CR20","unstructured":"BSG, Urteil vom 03.07.2022, Az. B 1 KR 25\/11\u202fR, juris Rn.\u00a015 mwN."},{"key":"5416_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/JCAS.JCAS_226_20","volume":"15","author":"AM Garg","year":"2022","unstructured":"Garg\u00a0AM, Mysore\u00a0V (2022) Dermatologic and Cosmetic Procedures in Pregnancy. J\u00a0Cutan Aesthet Surg 15:108\u2013117","journal-title":"J Cutan Aesthet Surg"},{"key":"5416_CR22","first-page":"665","volume":"57","author":"P Bozzo","year":"2011","unstructured":"Bozzo\u00a0P, Chua-Gocheco\u00a0A, Einarson\u00a0A (2011) Safety of skin care products during pregnancy. Can Fam Physician 57:665\u2013667","journal-title":"Can Fam Physician"},{"key":"5416_CR23","first-page":"783","volume":"116","author":"K Dathe","year":"2019","unstructured":"Dathe\u00a0K, Schaefer\u00a0C (2019) The Use of Medication in Pregnancy. Dtsch \u00c4rztebl Int 116:783\u2013790","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"5416_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/089033449701300219","volume":"13","author":"RL Breitzka","year":"1997","unstructured":"Breitzka\u00a0RL, Sandritter\u00a0TL, Hatzopoulos\u00a0FK (1997) Principles of drug transfer into breast milk and drug disposition in the nursing infant. J\u00a0Hum Lact 13:155\u2013158","journal-title":"J Hum Lact"},{"key":"5416_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0169-409X(03)00032-2","volume":"55","author":"JC Fleishaker","year":"2003","unstructured":"Fleishaker\u00a0JC (2003) Models and methods for predicting drug transfer into human milk. Adv Drug Deliv Rev 55:643\u2013652","journal-title":"Adv Drug Deliv Rev"},{"key":"5416_CR26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1001\/jamadermatol.2013.5768","volume":"149","author":"CC Chi","year":"2013","unstructured":"Chi\u00a0CC, Wang\u00a0SH, Mayon-White\u00a0R et\u00a0al (2013) Pregnancy outcomes after maternal exposure to topical corticosteroids: a\u00a0UK population-based cohort study. JAMA Dermatol 149:1274\u20131280","journal-title":"JAMA Dermatol"},{"issue":"Suppl 3","key":"5416_CR27","first-page":"iii28","volume":"47","author":"M Ostensen","year":"2008","unstructured":"Ostensen\u00a0M, Lockshin\u00a0M, Doria\u00a0A et\u00a0al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatol 47(Suppl 3):iii28\u201331","journal-title":"Rheumatol"},{"key":"5416_CR28","first-page":"678","volume":"27","author":"JA Martinez Lopez","year":"2009","unstructured":"Martinez Lopez\u00a0JA, Loza\u00a0E, Carmona\u00a0L (2009) Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 27:678\u2013684","journal-title":"Clin Exp Rheumatol"},{"key":"5416_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1517\/14740338.7.3.219","volume":"7","author":"CN Pisoni","year":"2008","unstructured":"Pisoni\u00a0CN, D\u2019Cruz\u00a0DP (2008) The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 7:219\u2013222","journal-title":"Expert Opin Drug Saf"},{"key":"5416_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40264-013-0034-x","volume":"36","author":"K Paziana","year":"2013","unstructured":"Paziana\u00a0K, Del Monaco\u00a0M, Cardonick\u00a0E et\u00a0al (2013) Ciclosporin use during pregnancy. Drug Saf 36:279\u2013294","journal-title":"Drug Saf"},{"key":"5416_CR31","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/rheumatology\/keaa592","volume":"60","author":"NW Andersson","year":"2021","unstructured":"Andersson\u00a0NW, Skov\u00a0L, Andersen\u00a0JT (2021) Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a\u00a0nationwide cohort study. Rheumatol 60:2317\u20132326","journal-title":"Rheumatol"},{"key":"5416_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1517\/14740338.2011.566555","volume":"10","author":"C Abarientos","year":"2011","unstructured":"Abarientos\u00a0C, Sperber\u00a0K, Shapiro\u00a0DL et\u00a0al (2011) Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf 10:705\u2013714","journal-title":"Expert Opin Drug Saf"},{"key":"5416_CR33","doi-asserted-by":"crossref","unstructured":"Barrau M, Roblin X, Andromaque L et\u00a0al (2023) What Should We Know about Drug Levels and Therapeutic Drug Monitoring during Pregnancy and Breastfeeding in Inflammatory Bowel Disease under Biologic Therapy? J\u00a0Clin Med 12:","DOI":"10.20944\/preprints202310.0116.v1"},{"key":"5416_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.cgh.2021.04.015","volume":"20","author":"S Volger","year":"2022","unstructured":"Volger\u00a0S, Scherl\u00a0E (2022) Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy. Clin Gastroenterol Hepatol 20:962\u2013963","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5416_CR35","doi-asserted-by":"publisher","first-page":"E1129","DOI":"10.1503\/cmaj.202391","volume":"193","author":"A Pham-Huy","year":"2021","unstructured":"Pham-Huy\u00a0A, Top\u00a0KA, Constantinescu\u00a0C et\u00a0al (2021) The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 193:E1129\u2013E36","journal-title":"CMAJ"},{"key":"5416_CR36","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1468-3083.2010.03925.x","volume":"25","author":"AR Ahmed","year":"2011","unstructured":"Ahmed\u00a0AR, Gurcan\u00a0HM (2011) Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris. J\u00a0Eur Acad Dermatol Venereol 25:1073\u20131079","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5416_CR37","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.jaip.2020.10.063","volume":"9","author":"AR Wolfson","year":"2021","unstructured":"Wolfson\u00a0AR, Mancini\u00a0CM, Banerji\u00a0A et\u00a0al (2021) Penicillin Allergy Assessment in Pregnancy: Safety and Impact on Antibiotic Use. J\u00a0Allergy Clin Immunol Pract 9:1338\u20131346","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5416_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40262-023-01211-z","volume":"62","author":"MR Hesse","year":"2023","unstructured":"Hesse\u00a0MR, Prins\u00a0JR, Hooge\u00a0MNL et\u00a0al (2023) Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part I\u2011Penicillins. Clin Pharmacokinet 62:221\u2013247","journal-title":"Clin Pharmacokinet"},{"key":"5416_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/dtb.2023.000001","volume":"61","author":"J Girling","year":"2023","unstructured":"Girling\u00a0J (2023) Aciclovir prophylaxis after varicella zoster exposure in pregnancy. Drug Ther Bull 61:82","journal-title":"Drug Ther Bull"},{"key":"5416_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sj.bdj.2016.299","volume":"220","author":"A Ouanounou","year":"2016","unstructured":"Ouanounou\u00a0A, Haas\u00a0DA (2016) Drug therapy during pregnancy: implications for dental practice. Br Dent\u00a0J 220:413\u2013417","journal-title":"Br Dent J"},{"key":"5416_CR41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1471-0528.2007.01290.x","volume":"114","author":"OT Mytton","year":"2007","unstructured":"Mytton\u00a0OT, McGready\u00a0R, Lee\u00a0SJ et\u00a0al (2007) Safety of benzyl benzoate lotion and permethrin in pregnancy: a\u00a0retrospective matched cohort study. BJOG 114:582\u2013587","journal-title":"BJOG"},{"key":"5416_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00001648-199907000-00016","volume":"10","author":"AE Czeizel","year":"1999","unstructured":"Czeizel\u00a0AE, Toth\u00a0M, Rockenbauer\u00a0M (1999) No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 10:437\u2013440","journal-title":"Epidemiology"},{"key":"5416_CR43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00105-022-05031-3","volume":"73","author":"LTH Thi","year":"2022","unstructured":"Thi\u00a0LTH, Eichner\u00a0A, Wohlrab\u00a0J (2022) Therapeutische Besonderheiten bei Erkrankungen der Mamillenhaut. Dermatologie 73:873\u2013879","journal-title":"Dermatologie"},{"key":"5416_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.2174\/156720112801323116","volume":"9","author":"SJ Bernick","year":"2012","unstructured":"Bernick\u00a0SJ, Kane\u00a0S (2012) Drug transfer to the fetus and to the breastfeeding infant: what do we know? Curr Drug Deliv 9:350\u2013355","journal-title":"Curr Drug Deliv"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05416-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05416-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05416-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:09:15Z","timestamp":1730794155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05416-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5416"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05416-6","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"30 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Wohlrab hat in den letzten 5\u00a0Jahren Zuwendungen f\u00fcr wissenschaftliche Projekte, klinische Studien, Vortr\u00e4ge, Beratung oder Lizenzzahlungen von folgenden Unternehmen erhalten: AbbVie, ACA, Actelion, Alexion, Allergika, Almirall, Amgen, Aristo, Astellas, BayPharma, Baxalta, Beiersdorf, Biogen, BMS, Boehringer Ingelheim, Bombastus, Celgene, Celltrion, Cerner Enviza France, Dermapharm, Ei, Eli-Lilly, Evolva, Evonik, FGK, Galderma, Gr\u00fcnenthal, GSK, Hexal, Icon, Incyte, Infectopharm, IQVIA, Janssen-Cilag, Jenapharm, Johnson\u00a0& Johnson, Klinge, Klosterfrau, Leo, L\u2019Or\u00e9al, Mavena, Medac, medACT, Medice, Medpace, Mibe, MSD, Mylan, Novaliq, Novartis, Parexel, Pfizer, PPD, QPS, Regeneron, Riemser, Rigi, Sandoz, Sanofi-Genzyme, Skinomics, Syneos, TFS, UBC, UCB, Wolff. A.\u00a0Schmidt erkl\u00e4rt keine Interessenkonflikte. A.\u00a0Eichner hat in den letzten 2\u00a0Jahren im Rahmen eines wissenschaftlichen Projektes von der Firma Novartis Bez\u00fcge erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}